ASU looks to set world record for largest ‘Walk on Mars’ map


March 12, 2019

For 18 years, Arizona State University’s Thermal Emission Imaging System (THEMIS) has been orbiting Mars onboard NASA’s Mars Odyssey spacecraft, collecting infrared images of the Martian surface.

More than 265,000 images have been collected over the mission’s lifetime, and the best of those have been painstakingly stitched together into a global mosaic, which was then printed on vinyl so that it could function as a durable, portable and walkable "Map of Mars." An idea of what ASU's Sun Devil Stadium would look like with a stadium-sized "Walk on Mars" map. The ASU School of Earth and Space Exploration is hoping to raise $35,000 to create this vinyl map to share Mars exploration with the public. Photo illustration courtesy of Charlie Leight/ASU Now and Jon Hill/ASU. Download Full Image

The vinyl map, which is currently the size of a basketball court, has been displayed at dozens of events and has been walked on by more than 5,000 participants. It is also slated to be on display at a "Mars on the Mall" event in front of the Smithsonian Institution's National Air and Space Museum in Washington, D.C., in May of this year.

While a basketball-court-size walkable map of Mars is impressive, the map is still too small to display the THEMIS images at full resolution. So, in celebration of THEMIS’ 18th anniversary, the ASU Mars team has a dream to see this map at its full resolution (100 meters per pixel), filling a certain nearby football stadium. 

To do so, they are seeking help from the public to raise $35,000 to make the dream a reality and to set a world record for the largest ever map of Mars.

“We want to share everything that THEMIS has taught us about Mars,” said ASU Mars researcher and map designer Jonathon Hill. “We are asking all members of the ASU community and Mars enthusiasts around the world to help us raise funds for a football-field-size map, so we can share the excitement of Mars exploration with as many people as possible.”

For this fundraising effort, the Mars team has set up an ASU Pitchfunder "Walk on Mars" webpage where the public can choose their donation amount, ranging from as little as $5 up to $762, which represents one penny for each of the 76,200 orbits Odyssey has made around Mars.

Donations to help create the map are being accepted throughout the month of March. All donors will be added to a mailing list and will receive exclusive updates about the map’s production and be the first to know when the map will be displayed, which the team hopes will be at Sun Devil Stadium in Tempe.

"From the beginning of Mars Odyssey's mission, the THEMIS team has been keen to convey the excitement of Mars exploration to students and the public," said THEMIS instrument principal investigator and Regents’ Professor, Philip Christensen. "This is the latest step in that process."

Celebrating 18 years in space

NASA’s Mars Odyssey spacecraft and ASU’s THEMIS camera launched to Mars on April 7, 2001. Today, it is the longest-lived robotic spacecraft in the history of Mars exploration. The instrument has acquired over 265,000 infrared images of the Martian surface since starting science operations in February 2002.

The THEMIS images were taken in Martian daytime at infrared wavelengths. For the vinyl map, each image was individually blended into the global map, one piece at a time. They cover the entire planet pole-to-pole and show every surface feature larger than 100 meters (roughly a football field) in size.

To provide the third dimension, the THEMIS image mosaic is combined with elevation data from another NASA instrument, the Mars Orbiter Laser Altimeter, or MOLA. This instrument's data is colored-coded to show elevation relative to Martian "sea level," which is the planet's average radius. Following terrestrial mapping practices, MOLA elevations below this altitude appear in cool colors, while the higher elevations are in warm tones that turn white at the highest elevations.

When fully funded, the football-field-sized map will be printed on durable vinyl ordinarily used for billboards and giant outdoor advertising wraps. Together with its plastic underpad, the giant map will be tough enough to let visitors walk upon it wearing socks or other soft foot coverings.

The vinyl "Walk on Mars" map will be transportable and available for display to the public anywhere with a football field (or a football-field-sized space). It is the hope of the ASU Mars team that this map be shared with communities nationwide. 

Karin Valentine

Media Relations & Marketing manager, School of Earth and Space Exploration

480-965-9345

 
image title

New plant-based vaccine at the forefront of more affordable HPV prevention

March 12, 2019

ASU researchers look for more efficient ways to guard against a variety of virus strains

Do you change the channel when you see an ad for the Gardasil vaccine? Maybe you are a man and don’t think you are at risk of acquiring cancer from HPV, maybe you aren’t sexually active, or maybe you don’t have the resources to get the vaccine.

But research shows that in addition to causing cervical cancer in women, certain strains have been linked to head and neck cancers in men. The Gardasil-9 vaccine protects against nine of the most cancer-associated strains of HPV, though there are more than 100 strains of HPV with possible adverse effects.

In light of this, Arizona State University is aggressively pursuing research aimed at understanding the underlying mechanisms behind the HPV infection and exploring preventative measures to stave off the virus.

In a recently published paper, researchers Hugh Mason, an associate professor in the School of Life Sciences and the Biodesign Center for Immunotherapy, Vaccines and Virotherapy, and Andy Diamos, a postdoctoral researcher with Mason’s lab, shed light on a more affordable, plant-based vaccine that stimulates a strong, broadly protective immune response against the virus. 

The current approach to the Gardasil vaccine is to produce strain-specific virus-like particles (or VLPs), which are composed of the virus’ capsid protein but none of its infection-causing DNA. The immune system still recognizes this protective shell of the virus and stimulates a response, but the vaccine does not contain any infectious agents. Each of these virus-like particles, however, only protects against one strain of HPV.

“If you are going to get protected against one of those, you won’t be protected against others. The way that the Gardasil vaccine has been trying to get around this is by essentially making a ton of VLPs and mixing them together into the same vaccine. Gardasil 9 is nine of these individual vaccines mixed into one,” Diamos said. “That is also why this is one of the most expensive vaccines on the market. It would be great if we could come up with a simpler vaccine that protects people against multiple strains of HPV.”

So the researchers set out to find a broadly protective target. Currently, the highly specific L1 capsid protein is utilized in vaccines, but another protein labelled L2 has not been explored in as much detail. The L2 protein is conserved across different strains of HPV, but it has been known to produce a poor immune response. If researchers were able to find a way to boost the immune response to this capsid protein, L2 could be used to produce broad-based protection against multiple variants of HPV.

“If you could convince your body’s immune system to care about this protein, then it could protect people against lots of strains at once. That was the idea behind our vaccine — to take this protein that is highly protective and find a way to make it highly immunogenic,” Diamos added.

The researchers utilized two different vaccine strategies. First, they made an HPV VLP by attaching the L2 protein to a pre-existing hepatitis B virus-like particle, and then they made a recombinant immune complex by fusing the L2 protein to an antibody.

Both of these approaches, when used in vaccines administered to mice, produced a strong immune response, but when delivered together, the improvement was impressive.

“What we found is that either of these two platforms (with this L2 antigen) can produce pretty strong antibody responses, but when we administer them together, we get a synergy that is greater than the additive effects,” Mason said.

The fact that these recombinant protein expression systems were produced in plants sidesteps some of the traditional challenges posed for other vaccines.

“We believe plants are a good model for expressing recombinant proteins because they are very easy to culture and thanks to developments in the last few years, we have been able to attain high levels of expression,” Mason said. “Using viral vectors, we deliver them into the plant system, they produce multiple copies of the gene that enhances the level of protein expression, and moreover, we can extract and purify the protein from plants, and purify it in a relatively straightforward way.”

“Ultimately, we think that plants can be a cheaper way to produce many of the recombinant proteins that are produced in mammalian culture systems, which are very expensive and require very expensive media and facilities to grow the cells.”

Although plant-based vaccines have a long way to go before they are approved and hit the market, they are associated with a lower cost in addition to a lower risk of external pathogens.

“The general idea is that when people make complex proteins, they use mammalian systems, and that’s problematic because they have to grow these mammalian cells in sterile bioreactors, which doesn’t scale up very well,” Diamos said. “Compare that to growing plants — you water them, you give them light and they grow. Plants also don’t harbor animal pathogens.” 

The current study describes a potential HPV vaccine while also assessing the validity of plant-based systems for vaccine development. The primary goal, however, was not to develop a full-fledged vaccine, but to better understand how different vaccine strategies improve the immune response to broadly protective HPV proteins.

“We see this as a way to better understand the immune response and what it will take to get a high enough antibody response to be protected or to obtain a longer-lasting immunity,” Mason said.

Such research is of particular medical significance as an effective HPV vaccine because it will not only suppress the symptoms associated with the virus, but also help prevent the emergence of HPV-linked cancer.

“For cervical cancer in women, HPV infection of the cervix will often ultimately lead to cancer and thus, the HPV vaccine is really an anti-cancer vaccine,” Mason said.  

This vaccine model is also viable for other infectious agents, which are being studied in Mason's lab. 

“We actually have an NIH grant being reviewed currently that focuses not on HPV but the influenza virus, using a highly conserved viral antigen for a broadly protective vaccine,” Mason said.

Eventually, the researchers would like to test the vaccine on humans or nonhuman primates, to further establish its safety and efficacy.

Gabrielle Hirneise

Assistant science writer , Biodesign Institute

480-433-4272